(24/7 MARKET NEWS) – OpGen, Inc. (Nasdaq: OPGN) announced, this morning, top line data from its successfully completed clinical trial for its Unyvero UTI Panel tests for a broad range of bacterial and fungal pathogens as well as antimicrobial resistance markers directly from urine specimens.
OpGen is trading higher in this morning’s premarket, at $0.2134, up $0.0884 (+70.72%), on 7.4 million shares traded.
Its 52-week range is $0.116 to $1.33. Its next inflection points are $0.23, $0.2865, and $0.38.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.